(19)

(11)

EP 4 333 794 A1

(12)

(43) Date of publication: 13.03.2024 Bulletin 2024/11 (21) Application number: 21939940.9 (22) Date of filing: 03.05.2021

(51) International Patent Classification (IPC):  A61K 8/02(2006.01) A61K 8/25(2006.01) A61K 8/04(2006.01) (52) Cooperative Patent Classification (CPC): A61K 9/1272; A61K 9/5123 (86) International application number: PCT/US2021/030443 (87) International publication number: WO 2022/235252 (10.11.2022 Gazette 2022/45)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN (71) Applicant: MCAL Therapeutics Inc. Park City, UT 84060 (US)	(72) Inventor: GADEK, Thomas Park City, Utah 84060 (US) (74) Representative: Algemeen Octrooi- en Merkenbureau B.V.  P.O. Box 645 5600 AP Eindhoven 5600 AP Eindhoven (NL)